0001178913-18-003085.txt : 20181204 0001178913-18-003085.hdr.sgml : 20181204 20181204160538 ACCESSION NUMBER: 0001178913-18-003085 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181203 FILED AS OF DATE: 20181204 DATE AS OF CHANGE: 20181204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wiley Matthew T. CENTRAL INDEX KEY: 0001759703 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36621 FILM NUMBER: 181216868 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 7670402 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001606645 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 BUSINESS PHONE: 97289316233 MAIL ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 FORMER COMPANY: FORMER CONFORMED NAME: Foamix Ltd. DATE OF NAME CHANGE: 20140428 4 1 zk1822341.xml OWNERSHIP DOCUMENT X0306 4 2018-12-03 0 0001606645 Foamix Pharmaceuticals Ltd. FOMX 0001759703 Wiley Matthew T. C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLTZMAN STREET REHOVOT L3 7670402 ISRAEL 0 1 0 0 Chief Commercial Officer Ordinary Shares 2018-12-03 4 A 0 50000 0.00 A 50000 D Options 4.06 2018-12-03 4 A 0 100000 0 A 2028-12-03 Ordinary Shares 100000 100000 D The equity incentive grants were approved by the Issuer's board of directors on the recommendation of a committee of the board on November 14, 2018 with a grant date of December 3, 2018. The ordinary shares underlying this restricted share unit award vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022. This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. Each option represents a contingent right to purchase one ordinary share of the issuer. The ordinary shares underlying these options vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on December 31, 2019 and 6.25% every three months thereafter) ending December 31, 2022. /s/ Ilan Hadar as attorney-in-fact for Matthew Wiley 2018-12-04